Roche Holding | ROG - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
AbbVie USD 5.23B 400M 2025-12
Alcon AG USD 1.5B 90M 2025-09
Almirall EUR 337.77M 14.83M 2025-12
Amgen USD 9.13B 316M 2025-12
AstraZeneca USD 8.14B 1.08B 2025-09
Bayer EUR 5.9B 1.34B 2025-09
Biogen USD 3.01B 854.3M 2025-12
Bristol-Myers Squibb USD 10.21B 5.52B 2025-12
Eli Lilly USD 7.27B 2.52B 2025-12
Fresenius EUR 1.23B 1.16B 2025-06
Fresenius Medical Care EUR 1.58B 326.57M 2025-12
Galapagos EUR 87.87M 23.41M 2025-12
Genmab DKK 1.72B 46M 2025-12
Gilead Sciences USD 7.33B 2.19B 2025-09
GlaxoSmithKline GBP 3.3B 303M 2025-09
GRIFOLS EUR 558.69M 194.13M 2025-06
Hikma Pharmaceutical USD 236M 48M 2025-06
Lonza CHF 719M 188M 2025-12
Merck EUR 2.25B 1.08B 2025-09
Merck USD 18.17B 10.16B 2025-09
Novartis USD 9.56B 2.9B 2025-09
Orion EUR 160.9M 63.3M 2025-12
Pfizer USD 1.34B 295M 2025-09
Philips EUR 1.91B 90M 2025-09
Recordati EUR 471.46M 129.91M 2025-09
Regeneron Pharmaceuticals USD 18.87B 16.36B 2025-12
Roche Holding CHF 7.55B 579M 2025-06
Sanofi EUR 7.66B 1.25B 2025-12
UCB EUR 1.57B 1.14B 2024-12